Estrogen Receptor and Immune Checkpoint Inhibitors: New Partners in Lung Cancer?

Karmele Valencia; Luis M Montuenga; Alfonso Calvo

doi:10.1158/1078-0432.CCR-23-1736

Estrogen Receptor and Immune Checkpoint Inhibitors: New Partners in Lung Cancer?

Clin Cancer Res. 2023 Oct 2;29(19):3832-3834. doi: 10.1158/1078-0432.CCR-23-1736.

Authors

Karmele Valencia^{1

2

3

4

5}, Luis M Montuenga^{1

2

3

5

6}, Alfonso Calvo^{1

2

3

5

6}

Affiliations

¹ Program in Solid Tumors, CIMA-University of Navarra, Pamplona, Spain.
² Consorcio de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
³ Navarra Health Research Institute (IDISNA), Pamplona, Spain.
⁴ Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.
⁵ Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain.
⁶ Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain.

PMID: 37548629
DOI: 10.1158/1078-0432.CCR-23-1736

Abstract

The influence of sex on immunotherapy response in patients with non-small cell lung cancer (NSCLC) had been studied with no clear conclusions. An article in this issue reports that a key determinant of response is not sex but the existence of a 17β-estradiol/ERα/PDL1 signaling loop in NSCLC. This intriguing result opens new therapeutic options. See related article by Anobile et al., p. 3958.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Estradiol / pharmacology
Estrogens
Humans
Immune Checkpoint Inhibitors / therapeutic use
Immunotherapy
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Receptors, Estrogen

Substances

Receptors, Estrogen
Estradiol
Immune Checkpoint Inhibitors
Estrogens